Aevi Genomic Medicine Announces Completion of Enrollment for Phase 2/3 SAGA Clinical Trial of AEVI-001 (NFC-1) in mGluR+ ADHD ...
PHILADELPHIA, PA--(Marketwired - Jan 4, 2017) - Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) Top-line results expected in Q1 2017 Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that enrollment is complete in the SAGA (Study of …